Skip to main content
LIFECORE BIOMEDICAL, INC. \DE\ logo

LIFECORE BIOMEDICAL, INC. \DE\ — Investor Relations & Filings

Ticker · LFCR ISIN · US5147661046 LEI · 549300EHBZ5OM9ND9O43 US Manufacturing
Open in API
Filings indexed 1,096 across all filing types
Latest filing 2015-10-01 Interim / Quarterly Rep…
Country US United States of America
Listing US LFCR

About LIFECORE BIOMEDICAL, INC. \DE\

https://www.lifecore.com/

Lifecore Biomedical is an integrated contract development and manufacturing organization (CDMO) that specializes in sterile injectable pharmaceutical drug products and medical devices. The company provides a full range of services, including specialty formulation, process development, aseptic filling, and final packaging, supporting products from clinical phases through to commercial supply. A key area of expertise is the handling of complex and highly viscous formulations. In addition to its CDMO capabilities, Lifecore is a primary producer of non-animal-sourced sodium hyaluronate (hyaluronic acid), offering it in various molecular weights and formats, including bulk material, hydrogels, and filled syringes and vials for diverse applications.

Recent filings

Filing Released Lang Actions
FORM 10-Q
Interim / Quarterly Report Q1 2016
2015-10-01 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 29, 2015, reporting the issuance of a press release announcing the company's consolidated financial results for the first quarter of fiscal year 2016. The text explicitly states that the press release is furnished as Exhibit 99.1 and that the information is being furnished, not filed, and is not incorporated by reference in other filings. The document itself does not contain detailed financial statements or substantive financial data but rather announces the release of financial results. The length of the document is 3138 characters, which is relatively short and consistent with an announcement rather than a full financial report. According to the classification rules, such a document is best classified as an Earnings Release (ER) because it is the initial announcement of quarterly financial results (key highlights only) provided via a press release attached to the 8-K. Therefore, the appropriate classification is ER with high confidence.
2015-09-29 English
FORM 4
Director's Dealing
2015-08-24 English
FORM DEF 14A
Proxy Solicitation & Information Statement
2015-08-24 English
FORM 4
Director's Dealing
2015-08-11 English
FORM 10-K
Annual Report FY 2015
2015-07-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.